Brokerages expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to post earnings per share (EPS) of ($0.04) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Stealth BioTherapeutics’ earnings. The firm is scheduled to announce its next earnings results on Wednesday, November 13th.
On average, analysts expect that Stealth BioTherapeutics will report full-year earnings of ($0.30) per share for the current fiscal year, with EPS estimates ranging from ($0.34) to ($0.25). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.13). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.04.
A number of research firms have recently commented on MITO. HC Wainwright set a $21.00 price objective on shares of Stealth BioTherapeutics and gave the stock a “buy” rating in a report on Friday, October 18th. Jefferies Financial Group set a $9.00 price objective on shares of Stealth BioTherapeutics and gave the stock a “hold” rating in a report on Tuesday, October 15th. Zacks Investment Research downgraded shares of Stealth BioTherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Nomura set a $28.00 price objective on shares of Stealth BioTherapeutics and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Stealth BioTherapeutics in a report on Friday, September 27th. They set an “overweight” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $21.86.
Shares of MITO traded up $0.04 during mid-day trading on Thursday, hitting $6.47. 2,700 shares of the company’s stock were exchanged, compared to its average volume of 21,879. The firm has a fifty day moving average of $6.42 and a two-hundred day moving average of $10.55. The stock has a market cap of $230.15 million and a price-to-earnings ratio of -4.59. Stealth BioTherapeutics has a twelve month low of $4.97 and a twelve month high of $20.99. The company has a quick ratio of 2.13, a current ratio of 2.13 and a debt-to-equity ratio of 0.54.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Featured Article: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.